Compare
Microbot Medical Inc. vs TELA Bio, Inc. vs Profound Medical Corp. vs PRO DEX Inc
| Latest fiscal year | Microbot Medical Inc. MBOTRevenue covers only part of its income (partial revenue) | TELA Bio, Inc. TELA | Profound Medical Corp. PROF | PRO DEX Inc PDEX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2026-06-30 |
| Revenue | n/a | $80.28M | $16.10M | $77.55M |
| Revenue growth (YoY) | n/a | +15.8% | +50.7% | +16.5% |
| Gross margin | n/a | 67.7% | 70.8% | 31.4% |
| Operating margin | n/a | -42.0% | -256.3% | 16.8% |
| Net margin | n/a | -48.4% | -264.4% | 17.6% |
| Net income | -$13.14M | -$38.83M | -$42.57M | $13.66M |
| EPS (Diluted) | -$0.29 | -$0.83 | $1.41 | $4.12 |
| Operating cash flow | -$13.05M | -$28.22M | -$38.21M | $7.24M |
| Free cash flow | -$13.11M | -$28.67M | -$38.38M | $6.76M |
| Cash & equivalents | $3.91M | $50.84M | $59.72M | $8.19M |
| Total assets | $81.54M | $81.42M | $77.47M | $74.51M |
| Total liabilities | $3.99M | $75.11M | $11.04M | $26.88M |
| Shareholders' equity | $77.55M | $6.31M | $66.43M | $47.63M |
| Return on year-end equity | -16.9% | -615.1% | -64.1% | 28.7% |
| Shares outstanding | 67.16M | 44.54M | 36.29M | 3.19M |
Revenue, most recent five fiscal years
| Fiscal year | Microbot Medical Inc. | TELA Bio, Inc. | Profound Medical Corp. | PRO DEX Inc |
|---|---|---|---|---|
| Latest | n/a | $80.28M Ended 2025-12-31 | $16.10M Ended 2025-12-31 | $77.55M Ended 2026-06-30 |
| 1 year earlier | n/a | $69.30M Ended 2024-12-31 | $10.68M Ended 2024-12-31 | $66.59M Ended 2025-06-30 |
| 2 years earlier | n/a | $58.45M Ended 2023-12-31 | $7.20M Ended 2023-12-31 | $53.84M Ended 2024-06-30 |
| 3 years earlier | n/a | $41.42M Ended 2022-12-31 | n/a | $46.09M Ended 2023-06-30 |
| 4 years earlier | n/a | $29.46M Ended 2021-12-31 | n/a | $42.04M Ended 2022-06-30 |